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ORIGINAL ARTICLE PARASITOLOGYValidation of an apicoplast genome target for the detection of Plasmodium
species using polymerase chain reaction and loop mediated isothermal
ampliﬁcationC. E. Oriero1,2,3, J.-P. van Geertruyden2, J. Jacobs3,4, U. D’Alessandro1,3,5 and D. Nwakanma1
1) Medical Research Council, Fajara, Gambia, 2) International Health Unit, University of Antwerp, 3) Institute of Tropical Medicine, Antwerp, 4) Department of
Microbiology and Immunology, University of Leuven, Belgium and 5) London School of Tropical Medicine and Hygiene, London, UKAbstractThe genome of the Plasmodium apicoplast, which has a higher copy number compared with current targets for molecular diagnosis of malaria,
appears to be a suitable target for detection of submicroscopic infections that are capable of sustaining transmission. Novel primers targeting
a conserved segment of the apicoplast (PFC10_AP|0010:rRNA) were designed and used in a number of different high throughput platforms
such as single-step PCR (ssPCR), nested PCR (nPCR) and loop-mediated isothermal ampliﬁcation (LAMP) for parasite detection. Replicates of
ten-fold serial dilutions of Plasmodium falciparum 3D7 DNA, with equivalent parasite density ranges of 200 000 to 0.2 parasites/μL, were used
to determine the limit of detection and repeatability of each assay. A panel of 184 archived DNA samples extracted from either EDTA whole
blood or dried blood spots, from across West Africa and South East Asia was used to determine the diagnostic performance of the assays. All
assays ampliﬁed the 2 parasites/μL dilution except the ssPCR, which ampliﬁed two of the three replicates. Using an 18S rRNA PCR as
reference, the sensitivity was 98% (95% CI 93–100%) for the LAMP assay, 87% (95% CI 79–93%) for ssPCR and 100% (95% CI
97–100%) for nPCR. Speciﬁcity was 91% (95% CI 83–96%) for LAMP, 82% (95% CI 72–90%) for ssPCR and 66% (95% CI 54–76%) for
nPCR. The apicoplast genome-based nPCR detected more positive samples overall than the reference method. Discrepant samples were
conﬁrmed as true positives using a probe-based real-time quantitative PCR assay. The results show that the apicoplast genome is a
suitable target for molecular diagnosis of malaria.
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E-mail: eoriero@mrc.gmIntroductionIn 2012, compared with the year 2000, mortality attributed to
malaria decreased by 45% worldwide and by 49% in Africa,
saving an estimated 3.3 million lives. However, malaria remains
a global health burden with an estimated 627 000 malaria deathsMicrobiol Infect 2015; 21: 686.e1–686.e7
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.02.025worldwide in 2012 [1]. In 2010, the WHO recommended prior
treatment conﬁrmation of clinical malaria by microscopy or a
rapid diagnostic test [2]. Although diagnostic capabilities have
recently been scaled up in the public sector, there is still a
signiﬁcant gap to meet the global target of universal access to
malaria diagnosis in both private and public sectors and at
community level by 2015 [3].
Asymptomatic carriers contribute signiﬁcantly to trans-
mission and commonly have low parasite densities [4]. How-
ever, the commonly used malaria diagnostic methods do not
reliably detect such low parasite densities. As malaria declines,
the number of samples to be screened to identify infected
individuals and to better target intervention measures willious Diseases. Published by Elsevier Ltd. All rights reserved
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programmes implementing active case detection with the aim of
reducing the human reservoir [6]. Identiﬁcation of malaria
parasites in peripheral blood samples can be most reliably
performed by detecting parasite DNA, which has transformed
the possibilities for diagnosis and investigation of malaria
epidemiology [7]. Polymerase chain reaction, the most widely
used molecular method for malaria diagnosis, has been modiﬁed
and optimized to improve diagnosis and accuracy of species
identiﬁcation [8–12], but a major disadvantage of PCR methods
is that they are almost impossible to perform at peripheral
health centres or in the ﬁeld. Hence, isothermal ampliﬁcation
methods that do not require multiple temperature cycles and
highly puriﬁed DNA template have been developed to address
these shortcomings [13–16].
Molecular diagnosis of malaria involves targeted ampliﬁcation
and detection of parasite genes, the most common being the
conserved small subunit ribosomal RNA (rRNA) 18S locus
[8,10,12,16]. Unlike many other eukaryotes with hundreds to
thousands of copies of the rRNA gene, P. falciparum has only
seven copies [17]. Several targets have been ampliﬁed in
different PCR and isothermal assays, including the mitochondria
[18,19] particularly the Cytochrome b gene [20], the stevor genes,
metabolizing enzyme genes and repeat regions within the
genome [21–23]. The apicoplast is a plastid organelle, homol-
ogous to the chloroplasts in plants and found in apicomplexan
parasites. It is semi-autonomous with its own genome and
expression machinery. Its genome copy number has been
estimated to be approximately 15 for P. falciparum [24,25]. The
apicoplast is therefore an obvious target for a diagnostic test
aiming to detect low-density infections because of the high copy
number but it has not been investigated for diagnostic pur-
poses. This study reports the optimization and validation of theFIG. 1. Conserved region of aligned apicoplast sequences of ﬁeld isolates
GamPf171, GamPf172, GamPf045, GamPf055, GamPf081, GamPf104, GamPf1
K1, RO33, T994, W2 and Wellcome) against the reference sequence (ApiPl
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inapicoplast of P. falciparum as a target for molecular diagnosis of
malaria using different molecular assays.Materials and methodsSamples
Replicates of ten-fold serial dilutions of laboratory cultures of
P. falciparum clone 3D7 prepared as described elsewhere [26]
were used to determine the limit of detection of the three
novel assays. A total of 184 DNA samples from different studies
archived at the Medical Research Council Unit, The Gambia
were analysed to test the utility of the novel target for malaria
diagnosis with three different molecular methods, namely a
single step PCR (ssPCR), nested PCR (nPCR) and loop-
mediated isothermal ampliﬁcation (LAMP). Samples were
selected to cover a wide geographical range, sample type and
parasite species; and comprised 80 samples from across three
West African countries, 88 samples from South East Asia, six
laboratory strains analysed in duplicates (3D7, W2, K1, Dd2,
T994 and HB3) and four negative controls (see Supporting
information, Table S1). All DNA samples had been extracted
with the QIAxtractor® robot (Qiagen GmbH, Hilden, Ger-
many) according to the manufacturers’ protocol and stored at
–20°C for a median period of 19 months (range 1–36 months).
Ethical approval was obtained from the Joint Gambian Gov-
ernment/MRC Ethics Committee.
Primer design and assay optimization
Plasmodium falciparum apicoplast sequences from 15 Gambian
isolates and eight laboratory clones were aligned against the
PlasmoDB reference sequence (ID: emb|X95275.2|) (Fig. 1).
Primers for both PCR and LAMP assays were designed from a(GamPf059, GamPf066, GamPf069, GamPf071, GamPf072, GamPf059,
16, GamPf824 and GamPf825) and laboratory strains (D10, DD2, FCC2,
asmoDB) on Lasergene® MegAlign™ (DNASTAR Inc.).
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 686.e1–686.e7
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of a ribosomal RNA gene (PFC10_AP|0010:rRNA) encoding on
the apicoplast genome. PCR primers were designed using PRIMER
EXPRESS® and LAMP primers were designed using PRIMER EXPLORER
V4. The primers were validated in silico with a web tool, THE
SEQUENCE MANIPULATION SUITE by Bioinformatics Organization,
Inc. (Hudson, MA, USA). All assays were optimized for tem-
perature and concentration of primers, deoxyribonucleotides
(dNTPs) as well as magnesium chloride (MgCl2) using triplicates
of three laboratory strains and two negative controls. After
optimization, an experienced laboratory technician indepen-
dently repeated the assays using the optimal conditions to assess
repeatability. Table 1 shows the list of successful primers.
Ampliﬁcation conditions
Nested PCR. Final ampliﬁcation reaction mixture for the outer
PCR contained 0.2 μM each of both forward and reverse
primers, 1× Thermopol buffer, 1 Unit of Taq DNA polymerase
(New England Biolabs, (UK) Ltd. Hitchin, Hertfordshire.),
0.2 mM of each dNTP and 2 μl of DNA per sample. Ampliﬁ-
cation conditions were 95°C for 5 min, 94°C for 30 s, 50°C for
30 s, 72°C for 30 s, repeated for 24 cycles, 72°C for 5 min. One
microlitre of the outer PCR product was used for the inner
PCR with similar conditions except annealing at 55°C and
repeated for 29 cycles. End product was determined by agarose
gel electrophoresis stained with ethidium bromide or by an
automated QIAxcel electrophoresis system (Qiagen GmbH).
The primers ampliﬁed a 138-bp fragment after the second
round of ampliﬁcation.
Single-step PCR. The outer LAMP primers were used to
amplify a 205-bp fragment in a single-step ampliﬁcation reac-
tion. The ﬁnal ampliﬁcation reaction mixture contained 0.3 μM
each of the forward and reverse LAMP primers, 1× Thermopol
buffer, 1 Unit of Taq DNA polymerase (New England Biolabs),
0.2 mM of each dNTP and 2 μl of DNA sample. The cyclingTABLE 1. List of successful primers used for loop-mediated isothe
assays
Name
LAMP primers
ApF3 (outer forward)
ApB3 (outer reverse)
ApLF (forward loop)
ApLB (reverse loop)
ApFIP (ApFIc + ApF2; forward inner)
ApBIP (ApBIc + ApF2; reverse inner)
Nested PCR primers
Api 1736 (outer forward)
Api 1976 (outer reverse)
Api 1808 (inner forward)
Api 1940 (inner reverse)
Single-step PCR Primers (Same as the LAMP outer primers)
ApF3 (forward)
ApB3 (reverse)
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectconditions were 95°C for 5 min, 93°C for 30 s, 56°C for 30 s,
72°C for 1 min, repeated for 34 cycles, 72°C for 5 min. End
product was determined same as the nPCR above.
LAMP ampliﬁcation conditions. Final ampliﬁcation reaction
mixtures contained 1.6 μM each of the inner primers (FIP and
BIP), 0.2 μMeach of the outer primers F3 and B3c, 0.8μMeach of
the loop primers (LPF and LPB), 1× Isothermal Ampliﬁcation
Buffer, 1 Unit of Bst 2.0 WarmStart™ DNA polymerase (New
England Biolabs), 1.0mMof each dNTP, 1.0mMMgCl2 and 2μl of
DNA sample. The reactionwas performed in a clear 96-well plate
at 65°C for 60 min in a water bath. End product was determined
both visually by naked eye, observing colour changes after adding
2 μL of 1000× SYBR® Green I (Life Technologies, Grand Island,
NY, USA) and electrophoresis and scored independently by two
observers. The LAMP primers ampliﬁed the expected loop-
structured fragments and speciﬁcity was conﬁrmed with a re-
striction digest using FokI (New England Biolabs) (Fig. 2).
Data analysis
Sensitivity and speciﬁcity of the optimized assays were calculated
using a species-speciﬁc 18S rRNA nested PCR assay (18S rRNA
PCR) [10] as the reference standard. Cohen’s κ (κ coefﬁcient)
was calculated to assess the degree of agreement between the
assays. The precision of the estimates was determined by
calculating 95% CI (rounded up to the nearest whole number)
for each test statistic. All statistical analysis was performed with
STATA 12 (StataCorp, College Station, TX, USA).
Discrepant results
Genus-speciﬁc real-time quantitative PCR (qPCR) primers and
probe targeting the 18S rRNA locus of Plasmodium spp [12].
was used to amplify samples with discrepant results to assess
the possibility of false-negative results with the reference
method. In this assay, samples were run in duplicates and intra-
assay coefﬁcient of variation (CV) was calculated for the Ctrmal ampliﬁcation (LAMP), nested PCR and single-step PCR
50 to 30 sequence
CGGATAAAAGTTACTCTAGGGATA
TTATATTAGATATGGACCGAACTG
GAGGTGCCAAACCTTTT
ATTAAAGCGATACGTGAGCTGG
GGATGCGATAAGCCGACATCTTTTCCGAGAGTCCATATTGAC
TTAAGGGTAAGTCTGTTCGCCTTCTCACGACGTTCTGAAC
AAATGTCGGTCTTAATGATCC
TATGGACCGAACTGTCTCACG
GGATAACAGGCTAATCTTTTCC
CTCACGTATCGCTTTAATAGG
CGGATAAAAGTTACTCTAGGGATA
TTATATTAGATATGGACCGAACTG
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 686.e1–686.e7
FIG. 2. Images of ampliﬁed DNA products on agarose gel electrophoresis (a); an automated electrophoresis system, QIAxcel (b); and LAMP visu-
alization by naked eye after addition of SYBR GreenI (c). Lane M, 100-bp DNA ladder; lane 1, loop-mediated isothermal ampliﬁcation (LAMP) +ve; lane
2, LAMP + ve FokI digest; lane 3, LAMP −ve; lane 4, single-step PCR (ssPCR) +ve; lane 5, ssPCR −ve; lane 6, nested PCR (nPCR) +ve; lane 7, nPCR −ve.
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resolve discrepancies and to provide absolute parasite densities
to determine the impact of low parasite density on speciﬁcity.ResultsLimit of detection and repeatability
Ten-fold serial dilutions of 3D7 DNA, with parasite density
ranging from the equivalent of 200 000 to 0.2 parasites/μL were
run in triplicate for each assay to determine the limit of
detection. All the assays ampliﬁed the 2 parasites/μL dilution
except ssPCR, which ampliﬁed in only two of the triplicates
(see Supporting information, Table S2). In addition, the nPCR
detected two of three replicates at aten-fold higher dilution of
0.2 parasites/μL, whereas LAMP and the reference method
both ampliﬁed only one of the three replicates. There were no
signiﬁcant differences in results obtained when the assays were
independently repeated.
Comparison using archived DNA samples
Out of the total 184 samples, 105 (57%) were detected as
positive by the reference 18S rRNA PCR assay, 82% of which
were P. falciparum mono-infections, 7% were Plasmodium vivax
mono-infections, 1% were Plasmodium malariae mono-
infections, and 10% were mixed infections of P. falciparum and
P. vivax. The test positivity was 60% (110/184) for LAMP, 57%
(105/184) for ssPCR and 72% for nPCR. With samples positive
for all methods, including the reference assay, the test positivity
was 48% (89/184) (Fig. 3). Of the 79 samples negative by the
reference assay, six were positive by all three methods, eight byClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InnPCR and ssPCR, one by nPCR and LAMP and 12 by nPCR
alone. There were no discrepancies between scores of the
LAMP assay by the two independent observers, regardless of
method of end-point determination. The nPCR assay had the
highest sensitivity, followed by LAMP and then ssPCR with only
87%. LAMP had the highest speciﬁcity, followed by ssPCR and
then nPCR (Table 2).
Degree of agreement
The κ coefﬁcient assessing the degree of agreement (after
correcting for agreement due to chance) with the reference
method was 0.9 for LAMP, 0.7 for ssPCR and 0.7 for nPCR
(Table 2). Comparing the LAMP assay with either ssPCR or
nPCR gave a κ coefﬁcient of 0.7.
Other parameters
Using McNemar’s chi square to test for marginal homogeneity,
there were no signiﬁcant differences in the performances of
LAMP and ssPCR compared with the reference method.
However, there was a signiﬁcant difference with nPCR
(McNemar’s χ2 = 27.00; Exact signiﬁcance probability <0.01).
Similarly, both LAMP and ssPCR showed no signiﬁcant differ-
ences by either geographic origin or sample type whereas with
nPCR there was a signiﬁcant difference by sample type, with
more discrepancies in the dried blood spot samples (McNe-
mar’s χ2 = 23.00; Exact signiﬁcance probability <0.01), but not
by geographic origin.
Discrepant results
Discrepancies occurred signiﬁcantly more with the dried blood
spot (85%, 23/27) compared to whole blood samples (15%, 4/fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 686.e1–686.e7
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FIG. 3. Venn diagram showing distribution of samples detected as positive by each of the methods. Proportions (%) refer to the total of 184 samples.
TABLE 2. Comparison of the optimized assays with the reference method (classifying 105 positive and 79 negative samples)
18S rRNA + ve 18S rRNA –ve Sensitivity Speciﬁcity Cohen’s κ coefﬁcient
LAMP + ve 103 7 98% (95% CI 93–100%) 91% (95% CI 83–96%) 0.9 (95% CI 0.8–1.0)
LAMP −ve 2 72
ssPCR + ve 91 14 87% (95% CI 79–93%) 82% (95% CI 72–90%) 0.7 (95% CI 0.6–0.8)
ssPCR −ve 14 65
nPCR + ve 105 27 100% (95% CI 97–100%) 66% (95% CI 54–76%) 0.7 (95% CI 0.6–0.8)
nPCR −ve 0 52
Abbreviations: LAMP, loop-mediated isothermal ampliﬁcation; nPCR, nested PCR; ssPCR, single-step PCR.
686.e5 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMI27). The qPCR analysis of these samples indicated low parasite
densities (<35 parasites/μL), with the ampliﬁcation curve
crossing the detection threshold after cycle 35, which corre-
sponds to parasite densities <20 parasites/μL in the standard
curve.
Usability of assays
All assays were high throughput, easy to use with optimized
protocols and were performed in a 96-well plate format.
Turnaround time for 88 samples with positive and negative
controls that could be analysed per 96-well plate was approx-
imately 300 min with the reference PCR method and nPCR,
150 min for ssPCR and 90–120 min for LAMP, depending onClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwhether end point determination was by naked eye or agarose
gel electrophoresis.DiscussionThe diagnosis of malaria has evolved rapidly within the last few
years. New and improved screening tools and strategies are
being developed, as currently available tools cannot promptly
detect low-density infections in the ﬁeld. Consequently, nucleic
acid tests are optimized for increased sensitivity and simpliﬁed
for ﬁeld deployability. Using a novel target with higher copy
number, the apicoplast genome, we validate its suitability forious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 686.e1–686.e7
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ular assays, including the LAMP assay that is potentially usable at
peripheral health facilities.
Although the primers were designed from aligned
P. falciparum sequences, they ampliﬁed non-falciparum species as
well, indicating that the target is possibly conserved across the
genus (see Supporting information, Fig. S1). Generally, the test
positivity by either LAMP or ssPCR assays targeting the api-
coplast genome was similar to the reference 18S rRNA PCR
method, although the LAMP assay had better agreement. The
apicoplast genome-based nPCR assay detected all samples
classiﬁed as positive by the other methods as well as 12 addi-
tional samples that were conﬁrmed to be low-density infections
by a very sensitive, probe-based qPCR assay. This explains the
lower speciﬁcity of nPCR as it detected an important number of
positive samples—conﬁrmed by the probe-based qPCR
assay—among samples considered negative by the reference
method. As expected, the majority (85%) of discrepancies
occurred with dried blood spot samples, probably because the
amount of blood screened per assay (approximately 4 μL of
blood in one 3-mm punch of dried blood spot) [27] would have
been much lower than in whole blood samples. The impact of
the sampling method on assay sensitivity is likely to be more
pronounced in low-density infections as parasite DNA would
be less efﬁciently extracted from dried ﬁlter paper blood spots
compared with whole blood samples.
The nPCR targeting the apicoplast genome was more sen-
sitive than the reference method, particularly for samples with a
parasite density <2 parasites/μL. Similar to other laboratory-
based PCR assays, its routine use in the ﬁeld would be chal-
lenging, though the use of real-time screening PCR in a mobile
laboratory has been recently reported [28]. Hence, the LAMP
assay that is less complex was developed alongside. Overall, the
sensitivity and speciﬁcity of the apicoplast genome-based LAMP
assay was similar to previously described LAMP assays targeting
the 18SrRNA gene or the mitochondria [13,15]. End-product
determination of the LAMP assay by observing colour
changes after addition of SYBR® Green I is practical for ﬁeld use
though it may be a problem for individuals with colour blind-
ness [29]. Colour charts of positive and negative results may be
needed, with systematic double reading.
A major limitation of this study is the unavailability of either
microscopy or rapid diagnostic test results for most of the
tested samples. As these are the currently used diagnostic tools
for malaria, it would have been interesting to evaluate the new
assays against standard diagnostic methods. Also, running rep-
licates of the discrepant samples could have increased the
sensitivity of the reference PCR method. In a recent study by
Hopkins et al., overall sensitivity of the reference nested PCRClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inassay was increased by repeating in three wells all samples that
tested negative in the ﬁrst run with any ampliﬁcation of the
expected fragment size scored as positive [30].
All the assays are high throughput and able to process
samples in a 96-well format. This is very important for the
potential use of ﬁeld-based molecular assays for mass screening
and treatment campaigns as the fast turn-around-time will
enable infected subjects to be treated within a short time. The
faster turn-around time of the LAMP assay and comparable
sensitivity with the reference 18S rRNA method would support
further assessment to determine its performance under ﬁeld
conditions. As more endemic regions begin to consider the
possibility of malaria elimination, ﬁeld-based molecular assays
are poised to be the favoured option for surveillance and tar-
geted interventions [31]. More sensitive targets are currently
being explored for potential ﬁeld-based molecular tests and the
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